AsiaPharm Of China, GlycoMar Of Scotland In R&D Tie
This article was originally published in PharmAsia News
China's AsiaPharm and GlycoMar, a biotech based in Scotland, have signed an agreement to conduct research and development for drugs based on marine glycomolecules. The agreement was reached as AsiaPharm, based in Shanghai, faces a takeover bid by MBK Partners, a Korean private-equity firm. Under the agreement with GlycoMar, the Scottish firm is to supply purified marine glycans to AsiaPharm to be studied for possible drug applications. The companies would collaborate on any candidates that result. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.